SLC17A9 expression levels in a pan‑cancer panel and validation of the role of SLC17A9 as a novel prognostic biomarker for osteosarcoma.

Previous studies have demonstrated the involvement of the solute carrier family 17 member 9 () in certain types of cancer; however, the precise role of is not well defined. In the present study, a comprehensive analysis was performed to determine the involvement of in a pan-cancer panel. First, data on expression levels from publicly available databases were obtained to determine expression profiles in various types of cancer. Next, the involvement of in the prognosis of patients, stemness indices and the immune microenvironment was examined in 34 types of cancer. Furthermore, CCK-8 and colony-formation assays were performed to determine the effect of on osteosarcoma (OSS) cells. In a pan-cancer panel, a difference in expression levels was observed in the tumor tissues as compared with healthy tissues. Furthermore, survival analysis revealed a significant association between expression levels and the prognosis of patients with various cancer types, including adrenocortical carcinoma, kidney renal clear cell carcinoma, glioblastoma, kidney renal papillary cell carcinoma, low grade glioma, liver hepatocellular carcinoma, mesothelioma, lung adenocarcinoma, skin cutaneous melanoma, uveal melanoma, stomach adenocarcinoma and OSS. The results of the present study revealed correlations between stemness indices, tumor immunity and expression levels. Furthermore, univariate and multivariate Cox regression analyses indicated that may be utilized as an independent risk factor for overall survival of patients with OSS. experiments demonstrated that promotes the proliferation and viability of OSS cells. Taken together, the results of the present study suggest an association between and the prognosis of patients as well as tumor immunity in various cancer types. may serve as a novel prognostic biomarker and target for improving the prognosis of patients with OSS.